In 9 normal volunteers, we studied the safety of rapid-rate transcranial magnetic stimulation (rTMS) applied to different scalp positions at various frequencies and intensities. Pure tone threshold audiometry showed temporary threshold shifts in 3 subjects. In the subject stimulated at the highest intensity, rTMS induced a focal, secondarily generalized seizure despite the absence of definite risk factors for seizures. Rapid-rate TMS did not result in any important changes in the neurological examination findings, cognitive performance, electroencephalogram, electrocardiogram, and hormone levels (prolactin, adrenocorticotropic hormone, thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone). In 10 additional subjects, the electromyographic activity in several contralateral muscles showed that trains of rTMS applied to the motor cortex induced a spread of cortical excitability. The spread of excitability depended on the intensity and frequency of the stimuli and probably constituted an early epileptogenic effect of rTMS. Guidelines for preventing the undesirable side effects of rTMS are offered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0168-5597(93)90094-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
J Prev Alzheimers Dis
October 2024
Yasuo Toda, Biogen Japan Ltd., 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Email: Phone: +81-3-3275-2074, Fax: +81-3-3275-1920, ORCID: 0000-0002-8737-5256.
Article Synopsis
- The global incidence of dementia, particularly Alzheimer's disease (AD), is increasing, prompting the need for effective treatments like aducanumab, which targets amyloid beta involved in AD.
- Aducanumab was approved by the FDA in June 2021 for treating early AD through an accelerated approval process, supported by data from two global phase 3 studies, EMERGE and ENGAGE.
- In these studies, Japanese participants with a confirmed diagnosis of mild cognitive impairment or mild AD dementia were evaluated for the drug's efficacy, safety, and pharmacokinetics, with results aligning closely with the overall findings.
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol
July 2024
US Oncology Network, 9180 Pinecroft Ave., Shenandoah, TX 77030, USA. Electronic address:
Introduction: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC.
Methods: This single arm, two-stage, phase 2 trial included those with measurable disease and 1-3 prior regimens.
Ketone-Based Alert System for Insulin Pump Failures.
J Diabetes Sci Technol
November 2023
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Allston, MA, USA.
Background: An increasing number of individuals with type 1 diabetes (T1D) manage glycemia with insulin pumps containing short-acting insulin. If insulin delivery is interrupted for even a few hours due to pump or infusion site malfunction, the resulting insulin deficiency can rapidly initiate ketogenesis and diabetic ketoacidosis (DKA).
Methods: To detect an event of accidental cessation of insulin delivery, we propose the design of ketone-based alert system (K-AS).
Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series.
Am J Health Syst Pharm
January 2024
University of California San Francisco, University of California San Francisco Benioff Children's Hospital Oakland, Oakland, CA, USA.
Purpose: Biosimilar tumor necrosis factor inhibitors (b-TNFi) reduce healthcare costs and maintain equal efficacy when compared to their originator counterparts (o-TNFi). Current practice is to start patients on a slower standard infusion rate during the initial transition from an o-TNFi to a b-TNFi. There is a knowledge gap around switching from rapid originator infusion to rapid biosimilar infusion in the pediatric inflammatory bowel disease (IBD) population.
View Article and Find Full Text PDFSafety outcomes of rapid- versus standard-infusion rate oxaliplatin.
J Oncol Pharm Pract
September 2024
University of New Mexico Hospital, Albuquerque, NM, USA.
Purpose: The National Comprehensive Cancer Network guidelines state that the oxaliplatin dose of 85 mg/m used in various gastrointestinal cancer regimens may be infused over a rapid rate of 85 min instead of the standard time of 120 min. We evaluated the safety outcomes of rapid administration of oxaliplatin compared to standard infusion.
Methods: We performed a retrospective, cohort study by chart review.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!